JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258281

Human VKORC1 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

VKORC1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 16 bp deletion in exon 1.

View Alternative Names

3-epoxide reductase subunit 1, EDTP308, FLJ00289, IMAGE3455200, MGC2694, MST134, MST576, Phylloquinone epoxide reductase, VKCFD2, VKOR, VKOR1_HUMAN, Vitamin K dependent clotting factors deficiency 2, Vitamin K epoxide reductase complex subunit 1, Vitamin K1 2, Vitamin K1 2,3-epoxide reductase subunit 1, Vitamin K1 epoxide reductase (warfarin sensitive)

1 Images
Sanger Sequencing - Human VKORC1 knockout HeLa cell lysate (AB258281)
  • Sanger seq

Unknown

Sanger Sequencing - Human VKORC1 knockout HeLa cell lysate (AB258281)

Homozygous : 16 bp deletion in exon 1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 16 bp deletion in exon 1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258281-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human VKORC1 knockout HeLa cell lysate", "number":"AB258281-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258281-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
VKORC1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Vitamin K epoxide reductase complex subunit 1 (VKORC1) also known as VKOR is an enzyme that plays an important role in the vitamin K cycle. This enzyme has a molecular mass of approximately 18 kDa. VKORC1 helps in reducing vitamin K 23-epoxide to its active hydroquinone form which is necessary for the gamma-carboxylation of vitamin K-dependent proteins. These proteins are mainly responsible for blood coagulation. VKORC1 expression is high in the liver where much of the synthesis of clotting factors occurs.
Biological function summary

VKORC1 is integral to the vitamin K cycle an essential process for activating vitamin K-dependent clotting factors. It operates within a complex with its protein partner VKORC1-like 1 (VKORC1L1). This partnership is important for maintaining effective blood coagulation. The active form of vitamin K produced by VKORC1 ensures the activity of several blood clotting factors especially factors II VII IX and X. Without proper function of VKORC1 these factors would remain inactive.

Pathways

The vitamin K cycle is where VKORC1 makes a significant impact and this cycle is vital for blood coagulation processes. Specifically VKORC1 reduces vitamin K epoxide working closely with gamma-glutamyl carboxylase (GGCX) another enzyme that modifies the glutamic acid residues on clotting factors. This modification is important for their proper functioning within the coagulation cascade. The interplay between VKORC1 and GGCX directly connects to the synthesis of active blood coagulation proteins.

VKORC1 mutations are notably linked to warfarin resistance and susceptibility to bleeding disorders. Warfarin is an anticoagulant that targets VKORC1 to prevent clot formation and variations in this protein can lead to altered drug response. Furthermore any dysfunction in VKORC1 may result in vitamin K epoxide reductase deficiency affecting coagulation and leading to increased bleeding risk. Mutations could also affect partner proteins like coagulation factors II and VII leading to disorders related to abnormal blood clotting processes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com